Articles From: - LifeVantage President & CEO to Present at WFDSA World Congress to - Galectin Therapeutics' Phase 1 Data Presented at AASLD Annual Meeting Advances GR-MD-02 Into Phase 2 Clinical Development


SALT LAKE CITY, Nov.
Sign-up for - LifeVantage President & CEO to Present at WFDSA World Congress investment picks
Brightcove Inc .
Sign-up for - Brightcove Appoints Kevin Rhodes as Chief Financial Officer investment picks
2014/11/10
VANCOUVER , Nov.
Sign-up for 2014/11/10 - Golden Queen reports financial results for the third quarter of 2014 investment picks
Net loss of $3.9M for second quarter includes one-time charge for workforce reduction Future operating expenses reduced through workforce and targeted cost reductions Quarterly dividend declared of $0.50 per share First MINI Z™ Handheld Z Backscatter® Screening systems shipped to customers BILLERICA, Mass., Nov.
Sign-up for - American Science and Engineering, Inc. Reports Results for Second Quarter Fiscal Year 2015 investment picks
IRVINE, Calif., Nov.
Sign-up for - Wheel Deals for Veterans, From the Editors at Autobytel investment picks
SAN DIEGO, Nov.
Sign-up for - TearLab to Participate in November Investor Conferences investment picks
- Expertise in global finance, M&A, business development - - Will join Actavis effective December 8, 2014 - DUBLIN , Nov.
Sign-up for - Actavis Names Maria Teresa Hilado Chief Financial Officer investment picks
McDonald's Corp.
Sign-up for - McDonald's October global same-store sales slump investment picks
JP Energy Partners LP (NYSE:JPEP) (“JP Energy”, “we,” “our,” or “us”) today announced its financial results for the quarter ended September 30, 2014.
Sign-up for - JP Energy Partners LP Announces Third Quarter 2014 Financial Results investment picks
GAMCO Investors, Inc. (NYSE:GBL) announced today that Vince Capurso has rejoined the management team of GAMCO as General Tax Counsel.
Sign-up for - Vince Capurso Re-joins GAMCO Investors as General Tax Counsel investment picks
http://media.marketwire.com/attachments/201006/7704_InphiLogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1157204&ProfileId=051205&sourceType=1 SANTA CLARA, CA --
Sign-up for - Inphi to Present at Upcoming Investor Conferences investment picks
-- Curis Provides Summary From Dose Escalation Stage of CUDC-907 Phase 1 Study Supporting Ongoing Expansion in DLBCL Patients – LEXINGTON, Mass., Nov.
Sign-up for - Curis Reports Third Quarter 2014 Financial Results and Pipeline Update investment picks
SAN CLEMENTE, Calif., Nov.
Sign-up for - ICU Medical, Inc. Announces Third Quarter 2014 Results investment picks
A strong cash position of approximately $29 million at the end of the third quarter of 2014, enabling the Company to continue to execute its R&D programs including the three ongoing Phase III studies in gastrointestinal indications: RHB-104 for Crohn's disease, RHB-105 for H.
Sign-up for - RedHill Biopharma Reports Results for the Third Quarter of 2014 investment picks
Kohl’s Department Stores (NYSE: KSS) announces today, in collaboration with Disney, that America can decide which aspiring singers and “Frozen” fans will be included as part of a Kohl’s holiday commercial to air during the American Music Awards at 8 p.m. EST/7 p.m. CST Sunday, Nov.
Sign-up for - Kohl’s and Disney Interactive Engage Families with Black Friday Campaign investment picks
Strengthening demand drove a 57% increase in design and manufacturing unit sales Expanding products and services fueled a 121% gain in healthcare revenue Materials gross profit margin was restored to 73.1% on improved mix and higher revenue Growing order book increased $14 million sequentially to $46 million ROCK HILL, S.C., Nov.
Sign-up for - 3D Systems Reports Third Quarter and Nine Months 2014 Financial Results investment picks
Stewart Title Commercial Services announced today its Dallas-Fort Worth office serviced a $265 million deal for client ClubCorp - The World Leader in Private Clubs ®, (NYSE: MYCC) – in connection with its acquisition of Sequoia Golf, an Atlanta-based golf course ownership and management company.
Sign-up for - Stewart Title® Commercial Services Closes $265M ClubCorp Acquisition Deal investment picks
Ascent Solar Technologies, Inc. (NASDAQ: ASTI ), a developer and manufacturer of state-of-the-art, flexible thin-film photovoltaic modules integrated into the company's EnerPlex™ series of consumer products, announced today that the company has signed Hitfar Concepts Ltd.
Sign-up for - Ascent Solar Announces Hitfar Concepts Ltd. as New Preferred EnerPlex Distributor in Canada investment picks
2014/11/10
HSINCHU, Nov.
Sign-up for 2014/11/10 - ChipMOS REPORTS OCTOBER 2014 REVENUE investment picks
2014/11/10
Program allows partners to improve listings accuracy and provides greater visibility for listing agents SEATTLE , Nov.
Sign-up for 2014/11/10 - Zillow Pro for Brokers Adds Achieve Realty investment picks
WESTPORT, Conn.
Sign-up for - Compass Diversified Holdings Announces Share Offering investment picks
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) (“Eagle” or the “Company”) today announced positive results from a recently-conducted clinical trial of its bendamustine hydrochloride (“HCl”) product, in which the dose was delivered in a 50mL admixture in ten minutes (the “rapidly infused product”) versus a 500mL admixture in the 60-minute infusion required for Treanda ® (bendamustine HCl). In this study, Eagle’s rapidly infused product was found to be bioequivalent to Treanda, which was the primary endpoint of the study.
Sign-up for - Eagle Pharmaceuticals Reports Positive Outcomes from Clinical Trial of Bendamustine HCl Product Delivered via Low-Volume, Rapidly Infused Admixture investment picks
2014/11/9
SINGAPORE and CHICAGO , Nov.
Sign-up for 2014/11/9 - CME Group Announces First Trade of New USD-Denominated Palm Olein Swaps investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of interim data from the C-SWIFT study exploring the potential of a candidate triple-therapy regimen consisting of the fixed-dose combination of grazoprevir/elbasvir (MK-5172/MK-8742, MK-5172A), the company’s investigational NS3/4A protease inhibitor and NS5A inhibitor, in combination with sofosbuvir, a nucleotide (NS5B) inhibitor for the treatment of chronic hepatitis C virus (HCV) infection.
Sign-up for - Interim Data from Proof-of-Concept Study of Merck’s Investigational Hepatitis C Treatment Grazoprevir/Elbasvir in Combination with a Nucleotide Inhibitor (C-SWIFT study) Presented at The Liver Meeting® investment picks
-Only Rentrak Provides the Official Global Movie Results- LOS ANGELES , Nov.
Sign-up for - Rentrak Announces Official Worldwide Box Office Results for Weekend of November 9, 2014 investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: - LifeVantage President & CEO to Present at WFDSA World Congress to - Galectin Therapeutics' Phase 1 Data Presented at AASLD Annual Meeting Advances GR-MD-02 Into Phase 2 Clinical Development
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent